+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID06066645

Study of iDose TR Implant with iStent Infinite Device for Adults with Open-Angle Glaucoma or Ocular Hypertension

Led by Glaukos Corporation · Updated on 2026-06-02

150

Participants Needed

1

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatments for adults with open-angle glaucoma or ocular hypertension who have elevated intraocular pressure. This study compares the safety and effects of the iStent infinite trabecular bypass system combined with a travoprost intraocular implant versus a sham procedure plus the same implant. The trial is a phase 4, multicenter, randomized, double-masked study sponsored by Glaukos Corporation. Participants will be randomly assigned to one of two groups one group will receive the iStent infinite device placement along with the travoprost implant, while the other group will undergo a sham procedure mimicking the iStent placement and receive the same travoprost implant. The travoprost implant is an anchored intracameral device containing the drug travoprost. The study follows participants for 12 months after treatment. During the study, participants will have their intraocular pressure monitored, focusing on changes from baseline over 3 months as the primary outcome. Safety and efficacy will be assessed through regular eye exams and measurements. The trial uses a double-masked design to reduce bias, and all participants will be followed closely over the study period to monitor treatment effects and any potential risks.

CONDITIONS

Brief Title

Travoprost Intraocular Implant + iStent Infinite

Research Team

S

Study Director

S

Study Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here